ABCB1 gene polymorphisms are not associated with treatment outcome in elderly acute myeloid leukemia patients

Clinical Pharmacology and Therapeutics

Volumn 80, Issue 5, 2006, Pages 427-439

  van der Holt, Bronno ^a   Van den Heuvel Eibrink, Marry M ^a   Van Schaik, Ron H N ^a   van der Heiden, Ilse P ^a   Wiemer, Erik A C ^a   Vossebeld, Paula J M ^a   Löwenberg, Bob ^a   Sonneveld, Pieter ^a  

^a ERASMUS MEDICAL CENTER   (Netherlands)

Author keywords

[No Author keywords available]

Indexed keywords

CYTARABINE; DAUNORUBICIN; ETOPOSIDE; GLYCOPROTEIN P INHIBITOR; MESSENGER RNA; MITOXANTRONE; MULTIDRUG RESISTANCE PROTEIN 1; VALSPODAR;

ACUTE GRANULOCYTIC LEUKEMIA; ADULT; AGED; ALLELE; ARTICLE; BLAST CELL; BONE MARROW; CANCER CHEMOTHERAPY; CANCER SURVIVAL; COHORT ANALYSIS; CONTROLLED STUDY; DNA POLYMORPHISM; DRUG EFFICACY; FEMALE; GENE EXPRESSION; GENETIC VARIABILITY; HUMAN; LEUKEMIA CELL; MAJOR CLINICAL STUDY; MALE; PRIORITY JOURNAL; PROSPECTIVE STUDY; PROTEIN EXPRESSION; PROTEIN FUNCTION; SINGLE NUCLEOTIDE POLYMORPHISM; STATISTICAL SIGNIFICANCE; SURVIVAL RATE; TREATMENT OUTCOME;

ACUTE DISEASE; AGED; AGED, 80 AND OVER; ALLELES; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; CLINICAL TRIALS, PHASE III; DISEASE-FREE SURVIVAL; FEMALE; GENE EXPRESSION REGULATION, NEOPLASTIC; GENE FREQUENCY; GENOTYPE; HAPLOTYPES; HUMANS; LEUKEMIA, MYELOID; MALE; MIDDLE AGED; MULTICENTER STUDIES; ORGANIC ANION TRANSPORTERS; P-GLYCOPROTEIN; POLYMORPHISM, SINGLE NUCLEOTIDE; RANDOMIZED CONTROLLED TRIALS; REVERSE TRANSCRIPTASE POLYMERASE CHAIN REACTION; RNA, MESSENGER; TREATMENT OUTCOME;

EID: 33751087230     PISSN: 00099236     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.clpt.2006.07.005     Document Type: Article

References (54)

1. Sonneveld P., and List A.F. Chemotherapy resistance in acute myeloid leukaemia. Best Pract Res Clin Haematol 14 (2001) 211-233
2. Klein I., Sarkadi B., and Varadi A. An inventory of the human ABC proteins. Biochim Biophys Acta 1461 (1999) 237-262
3. Juliano R.L., and Ling V. A surface glycoprotein modulating drug permeability in Chinese hamster ovary cell mutants. Biochim Biophys Acta 455 (1976) 152-162
4. Thiebaut F., Tsuruo T., Hamada H., Gottesman M.M., Pastan I., and Willingham M.C. Cellular localization of the multidrug-resistance gene product P-glycoprotein in normal human tissues. Proc Natl Acad Sci U S A 84 (1987) 7735-7738
5. Fojo A.T., Ueda K., Slamon D.J., Poplack D.G., Gottesman M.M., and Pastan I. Expression of a multidrug-resistance gene in human tumors and tissues. Proc Natl Acad Sci U S A 84 (1987) 265-269
6. Cordon-Cardo C., O'Brien J.P., Casals D., Rittman-Grauer L., Biedler J.L., Melamed M.R., et al. Multidrug-resistance gene (P-glycoprotein) is expressed by endothelial cells at blood-brain barrier sites. Proc Natl Acad Sci U S A 86 (1989) 695-698
7. Chen C.J., Chin J.E., Ueda K., Clark D.P., Pastan I., Gottesman M.M., et al. Internal duplication and homology with bacterial transport proteins in the mdr1 (P-glycoprotein) gene from multidrug-resistant human cells. Cell 47 (1986) 381-389
8. Ambudkar S.V., Kimchi-Sarfaty C., Sauna Z.E., and Gottesman M.M. P-glycoprotein: from genomics to mechanism. Oncogene 22 (2003) 7468-7485
9. Ambudkar S.V., Dey S., Hrycyna C.A., Ramachandra M., Pastan I., and Gottesman M.M. Biochemical, cellular, and pharmacological aspects of the multidrug transporter. Annu Rev Pharmacol Toxicol 39 (1999) 361-398
10. Kim R.B., Fromm M.F., Wandel C., Leake B., Wood A.J., Roden D.M., et al. The drug transporter P-glycoprotein limits oral absorption and brain entry of HIV-1 protease inhibitors. J Clin Invest 101 (1998) 289-294
11. Leith C.P., Kopecky K.J., Godwin J., McConnell T., Slovak M.L., Chen I.M., et al. Acute myeloid leukemia in the elderly: assessment of multidrug resistance (MDR1) and cytogenetics distinguishes biologic subgroups with remarkably distinct responses to standard chemotherapy. A Southwest Oncology Group study. Blood 89 (1997) 3323-3329
12. Leith C.P., Kopecky K.J., Chen I.M., Eijdems L., Slovak M.L., McConnell T.S., et al. Frequency and clinical significance of the expression of the multidrug resistance proteins MDR1/P-glycoprotein, MRP1, and LRP in acute myeloid leukemia: a Southwest Oncology Group Study. Blood 94 (1999) 1086-1099
13. Wuchter C., Leonid K., Ruppert V., Schrappe M., Buchner T., Schoch C., et al. Clinical significance of P-glycoprotein expression and function for response to induction chemotherapy, relapse rate and overall survival in acute leukemia. Haematologica 85 (2000) 711-721
14. van den Heuvel-Eibrink M.M., van der Holt B., te Boekhorst P.A., Pieters R., Schoester M., Lowenberg B., et al. MDR 1 expression is an independent prognostic factor for response and survival in de novo acute myeloid leukaemia. Br J Haematol 99 (1997) 76-83
15. Willman C.L. The prognostic significance of the expression and function of multidrug resistance transporter proteins in acute myeloid leukemia: studies of the Southwest Oncology Group Leukemia Research Program. Semin Hematol 34 (1997) 25-33
16. Legrand O., Simonin G., Zittoun R., and Marie J.P. Both P-gp and MRP contribute to drug resistance in AML. Leukemia 12 (1998) 1327-1328
17. Campos L., Guyotat D., Archimbaud E., Calmard-Oriol P., Tsuruo T., Troncy J., et al. Clinical significance of multidrug resistance P-glycoprotein expression on acute nonlymphoblastic leukemia cells at diagnosis. Blood 79 (1992) 473-476
18. Pirker R., Wallner J., Geissler K., Linkesch W., Haas O.A., Bettelheim P., et al. MDR1 gene expression and treatment outcome in acute myeloid leukemia. J Natl Cancer Inst 83 (1991) 708-712
19. Mickley L.A., Lee J.S., Weng Z., Zhan Z., Alvarez M., Wilson W., et al. Genetic polymorphism in MDR-1: a tool for examining allelic expression in normal cells, unselected and drug-selected cell lines, and human tumors. Blood 91 (1998) 1749-1756
20. Evans W.E., and McLeod H.L. Pharmacogenomics-drug disposition, drug targets, and side effects. N Engl J Med 348 (2003) 538-549
21. Marzolini C., Paus E., Buclin T., and Kim R.B. Polymorphisms in human MDR1 (P-glycoprotein): recent advances and clinical relevance. Clin Pharmacol Ther 75 (2004) 13-33
22. Ameyaw M.M., Regateiro F., Li T., Liu X., Tariq M., Mobarek A., et al. MDR1 pharmacogenetics: frequency of the C3435T mutation in exon 26 is significantly influenced by ethnicity. Pharmacogenetics 11 (2001) 217-221
23. Cascorbi I., Gerloff T., Johne A., Meisel C., Hoffmeyer S., Schwab M., et al. Frequency of single nucleotide polymorphisms in the P-glycoprotein drug transporter MDR1 gene in white subjects. Clin Pharmacol Ther 69 (2001) 169-174
24. Kioka N., Tsubota J., Kakehi Y., Komano T., Gottesman M.M., Pastan I., et al. P-glycoprotein gene (MDR1) cDNA from human adrenal: normal P-glycoprotein carries Gly185 with an altered pattern of multidrug resistance. Biochem Biophys Res Commun 162 (1989) 224-231
25. Kim R.B., Leake B.F., Choo E.F., Dresser G.K., Kubba S.V., Schwarz U.I., et al. Identification of functionally variant MDR1 alleles among European Americans and African Americans. Clin Pharmacol Ther 70 (2001) 189-199
26. Hoffmeyer S., Burk O., von Richter O., Arnold H.P., Brockmoller J., Johne A., et al. Functional polymorphisms of the human multidrug-resistance gene: multiple sequence variations and correlation of one allele with P-glycoprotein expression and activity in vivo. Proc Natl Acad Sci U S A 97 (2000) 3473-3478
27. Fellay J., Marzolini C., Meaden E.R., Back D.J., Buclin T., Chave J.P., et al. Swiss HIV Cohort Study. Response to antiretroviral treatment in HIV-1-infected individuals with allelic variants of the multidrug resistance transporter 1: a pharmacogenetics study. Lancet 359 (2002) 30-36
28. Nakamura T., Sakaeda T., Horinouchi M., Tamura T., Aoyama N., Shirakawa T., et al. Effect of the mutation (C3435T) at exon 26 of the MDR1 gene on expression level of MDR1 messenger ribonucleic acid in duodenal enterocytes of healthy Japanese subjects. Clin Pharmacol Ther 71 (2002) 297-303
29. Sakaeda T., Nakamura T., Horinouchi M., Kakumoto M., Ohmoto N., Sakai T., et al. MDR1 genotype-related pharmacokinetics of digoxin after single oral administration in healthy Japanese subjects. Pharm Res 18 (2001) 1400-1404
30. van der Holt B., Lowenberg B., Burnett A.K., Knauf W.U., Shepherd J., Piccaluga P.P., et al. The value of the MDR1 reversal agent PSC-833 in addition to daunorubicin and cytarabine in the treatment of elderly patients with previously untreated acute myeloid leukemia (AML), in relation to MDR1 status at diagnosis. Blood 106 (2005) 2646-2654
31. Cheson B.D., Cassileth P.A., Head D.R., Schiffer C.A., Bennett J.M., Bloomfield C.D., et al. Report of the National Cancer Institute-sponsored workshop on definitions of diagnosis and response in acute myeloid leukemia. J Clin Oncol 8 (1990) 813-819
32. Lowenberg B., van Putten W.L., Touw I.P., Delwel R., and Santini V. Autonomous proliferation of leukemic cells in vitro as a determinant of prognosis in adult acute myeloid leukemia. N Engl J Med 328 (1993) 614-619
33. Mechetner E.B., and Roninson I.B. Efficient inhibition of P-glycoprotein-mediated multidrug resistance with a monoclonal antibody. Proc Natl Acad Sci U S A 89 (1992) 5824-5828
34. Sugawara I., Kataoka I., Morishita Y., Hamada H., Tsuruo T., Itoyama S., et al. Tissue distribution of P-glycoprotein encoded by a multidrug-resistant gene as revealed by a monoclonal antibody, MRK 16. Cancer Res 48 (1988) 1926-1929
35. van den Heuvel-Eibrink M.M., Wiemer E.A., Prins A., Meijerink J.P., Vossebeld P.J., van der Holt B., et al. Increased expression of the breast cancer resistance protein (BCRP) in relapsed or refractory acute myeloid leukemia (AML). Leukemia 16 (2002) 833-839
36. van Schaik R.H., van der Werf M., van der Heiden I.P., Dorrestein S., Brosens R., Thiadens A., et al. CYP3A4, CYP3A5 and MDR-1 variant alleles in the Dutch Caucasian population [abstract]. Clin Pharmacol Ther 73 (2003) P42
37. Johne A., Kopke K., Gerloff T., Mai I., Rietbrock S., Meisel C., et al. Modulation of steady-state kinetics of digoxin by haplotypes of the P-glycoprotein MDR1 gene. Clin Pharmacol Ther 72 (2002) 584-594
38. In: Mitelman F. (Ed). ISCN 1995: an international system for human cytogenetic nomenclature: 1995 (1995), S. Karger, Basel
39. Hardy G.H. Mendelian proportions in a mixed population. Science 28 (1908) 49-50
40. Hosmer D.W., and Lemeshow S. Applied logistic regression (1989), John Wiley & Sons, New York
41. Kaplan E., and Meier P. Nonparametric estimation from incomplete observations. J Am Stat Assoc 53 (1958) 457-481
42. Cox D.R. Regression models and life tables. J R Stat Soc 34 (1972) 187-220
43. Mantel N. Evaluation of survival data and two new rank order statistics arising in its consideration. Cancer Chemother Rep 50 (1966) 163-170
44. Illmer T., Schuler U.S., Thiede C., Schwarz U.I., Kim R.B., Gotthard S., et al. MDR1 gene polymorphisms affect therapy outcome in acute myeloid leukemia patients. Cancer Res 62 (2002) 4955-4962
45. Plasschaert S.L., Groninger E., Boezen M., Kema I., de Vries E.G., Uges D., et al. Influence of functional polymorphisms of the MDR1 gene on vincristine pharmacokinetics in childhood acute lymphoblastic leukemia. Clin Pharmacol Ther 76 (2004) 220-229
46. Jamroziak K., Mlynarski W., Balcerczak E., Mistygacz M., Trelinska J., Mirowski M., et al. Functional C3435T polymorphism of MDR1 gene: an impact on genetic susceptibility and clinical outcome of childhood acute lymphoblastic leukemia. Eur J Haematol 72 (2004) 314-321
47. Oselin K., Gerloff T., Mrozikiewicz P.M., Pahkla R., and Roots I. MDR1 polymorphisms G2677T in exon 21 and C3435T in exon 26 fail to affect rhodamine 123 efflux in peripheral blood lymphocytes. Fundam Clin Pharmacol 17 (2003) 463-469
48. Broxterman H.J., Sonneveld P., Feller N., Ossenkoppele G.J., Wahrer D.C., Eekman C.A., et al. Quality control of multidrug resistance assays in adult acute leukemia: correlation between assays for P-glycoprotein expression and activity. Blood 87 (1996) 4809-4816
49. van den Heuvel-Eibrink M.M., Wiemer E.A., de Boevere M.J., van der Holt B., Vossebeld P.J., Pieters R., et al. MDR1 gene-related clonal selection and P-glycoprotein function and expression in relapsed or refractory acute myeloid leukemia. Blood 97 (2001) 3605-3611
50. Lowenberg B., Downing J.R., and Burnett A. Acute myeloid leukemia. N Engl J Med 341 (1999) 1051-1062
51. Mathijssen R.H., Marsh S., Karlsson M.O., Xie R., Baker S.D., Verweij J., et al. Irinotecan pathway genotype analysis to predict pharmacokinetics. Clin Cancer Res 9 (2003) 3246-3253
52. Morita Y., Sakaeda T., Horinouchi M., Nakamura T., Kuroda K., Miki I., et al. MDR1 genotype-related duodenal absorption rate of digoxin in healthy Japanese subjects. Pharm Res 20 (2003) 552-556
53. Chowbay B., Li H., David M., Cheung Y.B., and Lee E.J. Meta-analysis of the influence of MDR1 C3435T polymorphism on digoxin pharmacokinetics and MDR1 gene expression. Br J Clin Pharmacol 60 (2005) 159-171
54. Wang D., Johnson A.D., Papp A.C., Kroetz D.L., and Sadee W. Multidrug resistance polypeptide 1 (MDR1, ABCB1) variant 3435C>T affects mRNA stability. Pharmacogenet Genomics 15 (2005) 693-704